Yiheng Capital Management L.P. Reduces Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Yiheng Capital Management L.P. decreased its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 11.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 750,261 shares of the company's stock after selling 97,630 shares during the period. Viridian Therapeutics makes up approximately 0.6% of Yiheng Capital Management L.P.'s holdings, making the stock its 10th largest holding. Yiheng Capital Management L.P. owned approximately 0.95% of Viridian Therapeutics worth $14,383,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd purchased a new position in shares of Viridian Therapeutics during the 4th quarter valued at about $26,000. AlphaQuest LLC grew its position in Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after acquiring an additional 1,519 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Viridian Therapeutics during the third quarter worth approximately $149,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Viridian Therapeutics in the 3rd quarter worth approximately $208,000. Finally, E Fund Management Co. Ltd. purchased a new stake in shares of Viridian Therapeutics in the 4th quarter valued at $235,000.

Viridian Therapeutics Trading Down 4.3 %

VRDN stock traded down $0.66 on Tuesday, reaching $14.80. The company's stock had a trading volume of 755,095 shares, compared to its average volume of 1,155,457. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The business has a fifty day simple moving average of $16.98 and a two-hundred day simple moving average of $19.77. The firm has a market cap of $1.21 billion, a PE ratio of -3.43 and a beta of 1.05. Viridian Therapeutics, Inc. has a 12-month low of $11.40 and a 12-month high of $27.20.

Remove Ads

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.24. The firm had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. As a group, research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on VRDN. HC Wainwright reiterated a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research report on Monday, December 16th. Royal Bank of Canada boosted their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research note on Tuesday, December 17th. Needham & Company LLC restated a "buy" rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Finally, TD Cowen assumed coverage on Viridian Therapeutics in a research note on Monday, November 25th. They set a "buy" rating for the company. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Viridian Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.